The combination drug elbasvir/grazoprevir (Zepatier) from Merck has received FDA approval, according to a Medscape report.
Zepatier is designed to treat hepatitis C genotypes 1 and 4. The drug does not require the use of interferon, according to the report. Merck’s newly approved drug will compete with Gilead Sciences’ Harvoni and AbbVie’s Viekira Pak.